Document is current
Any future updates will be listed below
-
Authors
Lu, Ni
Liu, Li
Cao, Yigeng
Zhang, Rongli
Zhai, Weihua
Chen, Xin
Ma, Qiaoling
Yang, Donglin
Pang, Aiming
Wei, Jialin
He, Yi
Feng, Sizhou
Han, Mingzhe
Jiang, Erlie
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04645199 at ClinicalTrials.govDocuments that mention this clinical trial
Efficacy and safety of mitoxantrone hydrochloride liposome-containing regimens in treating refractory/relapsed acute myeloid leukemia
https://doi.org/10.1007/s12672-025-02526-y
-
Funding
Funding for this research was provided by:
National Key R&D Program of China (2023YFC2508900)
CAMS Innovation Fund for Medical Sciences, CIFMS (2023-I2M-2-007)
National Natural Science Foundation of China (82070192)
Haihe Laboratory of Cell Ecosystem Innovation Fund (22HHXBSS00034)
Tianjin Natural Science Foundation (23JCZXJC00220)
- License Information
-
More Information
Article History
Received: 27 November 2024
Accepted: 28 April 2025
First Online: 12 May 2025
Declarations
:
: The Ethics Committee of Blood Diseases Hospital, Chinese Academy of Medical Sciences (IIT2021011-EC-1) approved the research protocol. This study follows the Declaration of Helsinki. This study was registered with clinicaltrials.gov (Identifier, NCT04645199) in 27/11/2020. All patients provided written and oral informed consent.
: The subjects gave written informed consent for the publication of any associated data.
: The authors declare no competing interests.
